ClinicalTrials.gg
RecruitingNCT05941520Updated Nov 18, 2026

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

A Phase 2 interventional study of Acolbifene Hydrochloride and Biospecimen Collection in Breast Atypical Hyperplasia, Breast Carcinoma and Breast Ductal Carcinoma In Situ, sponsored by National Cancer Institute (NCI). Recruiting at 4 sites in United States. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionCarcinoma, Intraductal, NoninfiltratingRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Intraductal, Noninfiltrating
Why
  1. The study's listed conditions name Carcinoma, Intraductal, Noninfiltrating, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
35 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Carcinoma, Intraductal, Noninfiltrating by National Cancer Institute (NCI) — 3 open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · National Cancer Institute (NCI).

Planned enrollment
4th of 13
80 · median 65
Started
2024
with 1 other
Phase 2
5 of 13
3 open now
Registered
11th of 13
by date

Among the 13 studies in Carcinoma, Intraductal, Noninfiltrating by National Cancer Institute (NCI), this one is the 4th largest by planned enrollment, is one of 2 that started in 2024, is one of 5 in phase 2, and was the 11th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

3 of the 13 studies in Carcinoma, Intraductal, Noninfiltrating by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 35 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Intraductal, Noninfiltrating by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for patients at increased risk for breast cancer is to undergo yearly breast magnetic resonance imaging or ultrasound in addition to yearly mammogram. Premenopausal women at very high lifetime risk for breast cancer (greater than 50%) can consider preventive removal (mastectomy) of both breasts. Premenopausal women age 35 or older with a prior diagnosis of atypical hyperplasia, lobular carcinoma in situ, or an estimated 10-year risk of greater than or equal to 3% or estimated 10-year risk of greater than or equal to 2-5 times that of the average woman (depending on age) may be advised to consider five years of standard dose tamoxifen. Standard dose tamoxifen is four times the dose used in this study. Estrogen can cause the development and growth of breast cancer cells. Acolbifene and tamoxifen blocks the use of estrogen by breast cells. This study may help researchers measure the effects of acolbifene and low dose tamoxifen on markers of breast cancer risk in mammogram imaging, breast tissue, and in blood samples.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine if there is a difference in change in expression of the endocrine resistance gene anterior gradient 2 (AGR2) in benign breast tissue of premenopausal women at increased risk for breast cancer randomized to acolbifene 20 mg versus (vs) tamoxifen 5 mg orally daily for 6 months.

SECONDARY OBJECTIVES:

I. To determine if there is significant within-arm effect of 6 months of acolbifene 20 mg or tamoxifen 5 mg as assessed on the Estrogen Response Gene Index (ERGI) in benign breast tissue.

II. To determine if there is significant within-arm effect of 6 months of acolbifene 20 mg or tamoxifen 5 mg on mammographic density as measured by change in fibroglandular volume (FGV) and mammographic percent dense volume.

III. To determine if there is a significant within-arm effect of 6 months of acolbifene 20 mg or tamoxifen 5 mg on Menopause-Specific Quality of Life Questionnaire (MENQOL) or Hot Flash Score.

EXPLORATORY OBJECTIVES:

I. Assess within arm change in breast epithelial cell protein expression of Ki-67 in specimens with >= 2% baseline Ki-67.

II. Assess within arm change in bioavailable serum estradiol, testosterone, progesterone.

III. Association of baseline anti-Mullerian hormone (AMH) (>= 1 ng/ml associated with normal ovarian reserve) with 6-month serum estradiol and change in tissue estrogen responsive gene expression (ERGI and AGR2).

IV. Association of tamoxifen and acolbifene parent drug and active metabolite levels with change in tissue estrogen response genes and mammographic density.

V. Assess within arm change of AGR2, Forkhead box protein A1 (FOXA1), estrogen receptor (ER), progesterone receptor (PR) proteins on residual fixed specimens acquired by random periareolar fine needle aspiration (RPFNA) and processed to blocks.

VI. Assess within arm change in metabolic measures including triglycerides, measures of insulin sensitivity and thyroid binding globulin (Kansas University Medical Center [KUMC] participants only).

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients receive acolbifene orally (PO) once daily (QD) for 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo three-dimensional (3D) mammography and collection of blood samples during screening and at the end of acolbifene treatment. In addition, patients undergo RPFNA during screening and on day 1-10 of their menstrual cycle, or if not menstruating, at the convenience of the patient and study staff.

GROUP II: Patients receive tamoxifen PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D mammography and collection of blood samples during screening and at the end of tamoxifen treatment. In addition, patients undergo RPFNA during screening and day 1-10 of their menstrual cycle, or if not menstruating, at the convenience of the patient and study staff.

After completion of study treatment, patients are followed up between 21-35 days.

03

Conditions studied

  • Breast Atypical Hyperplasia
  • Breast Carcinoma
  • Breast Ductal Carcinoma In Situ
  • Breast Lobular Carcinoma In Situ
04

In context

Carcinoma, Intraductal, Noninfiltrating Reclassified

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

This study's planned enrollment of 80 is above the median of 66 across 209 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Compared within Carcinoma, Intraductal, Noninfiltrating, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
35 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 35 years
  • Considered clinically premenopausal
  • Having regular menstrual cycles (between 21 and 35 days) unless a device such as progestin containing intrauterine device (IUD) (e.g., Mirena IUD) or oral contraceptives is being used which suppresses menstrual periods, or premenopausal women who have undergone a hysterectomy, but have at least one intact ovary
  • Not considering pregnancy for at least 12 months
  • Women of capacity who are heterosexually active must be willing to have used effective birth control precautions for 8 weeks prior to fine needle aspiration and be willing to continue for 8 weeks after study completion as tamoxifen may have teratogenic effects on the developing fetus. Reproductive and developmental toxicity studies have not been conducted with acolbifene. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must stop study drug and inform her study physician immediately.

    • For women who are heterosexually active not using oral contraceptive (progestin alone or estrogen plus a progestin), two of the following are recommended but woman must agree to at least one of the following methods:

      • IUD non-hormonal or hormone containing (usually a progestin) intrauterine device (IUD) or rings. Any of these should have been inserted at least 8 weeks prior to RPFNA.
      • Barrier method (such as condoms and diaphragms or cervical caps with or without a spermicide)
      • Partner has had a vasectomy.
    • For women who are heterosexually active using oral contraceptive (progestin alone or estrogen plus a progestin), woman must agree to at least a non- hormonal IUD or a barrier method (below) or her partner must have had a vasectomy:

      • Non-hormonal IUD
      • Barrier method (such as condoms and diaphragms or cervical caps with or without a spermicide)
      • Partner has had a vasectomy
  • Must have increased breast cancer risk as predicted by any one or more of the conditions listed below or increased model calculated risk as below:

    • Any one or more of the following conditions associated with increased risk (condition must be documented in electronic medical record or copy of relevant pathology or genetic testing reports submitted with the eligibility checklist)

      • A prior at any time in the past showing ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), atypical hyperplasia. (If DCIS must have been treated by mastectomy or local excision +/- radiation with this treatment completed at least 3 months prior to screening with RPFNA)
      • High or moderate penetrance risk pathogenic or likely pathogenic germline gene mutation in ATM, BARD1, BRIP1, CDH1, CHEK2, MSH6, NBN, NF1, PTEN, PMS2, RAD51C, RAD51D, TP53, BRCA2, or PALB2
      • High polygenic risk score (Life-time risk of >= 2x average or 25%)
      • Breast cancer in a first or second degree relative (female or male) with onset under age 50. First degree relative is defined as parent, sibling, or child. Second degree relative is defined as grandparent, uncle, aunt, nephew, niece, half-sibling, grandchild or first cousin
      • Two or more affected first or second-degree relatives from either the maternal or paternal lineage without regard to age
      • Bilateral breast cancer or breast and ovarian cancer in the same first or second degree relative without regard to age.
      • High mammographic density defined as either visual estimate of area of density (VAS) > 50%, or Volpara (Trademark) >= 15% dense volume (Volpara d) or Breast Imaging Reporting and Data System (BIRADS) assessment of extremely dense (BIRADs D)
      • Chest irradiation prior to age 30
    • Alternatively, instead of conditions listed above, an increased risk of breast cancer as calculated by International Breast Cancer Intervention Study Version 8 (IBIS 8), or Breast Cancer Surveillance Consortium (BCSC) 3 by one or more of the following criteria:

      • 10-year risk of breast cancer of >= 3%
      • Increase in age specific 10-year relative risk by age group

        • Age 35-39 10-year relative risk of >= 5X that for age group
        • Age 40-44 10-year risk of >= 4X that for age group
        • Age 45 and up 10-year risk of >= 2X
      • IBIS Version 8 Remaining lifetime risk of >= 25% or >= 2X that of population
    • A copy of the output of model calculations from IBIS 8 (https://ems-trials.org/riskevaluator/), or BCSC version 3.0 (https://tools.bcsc-scc.org/BC5yearRisk/calculator.htm) online tools, if used for qualifying risk assessment, or polygenetic risk score should be submitted with the eligibility checklist. Otherwise, these risk qualifying factors need to be documented in the medical record if that is considered the source document
  • Women must have at least 1 unaffected untreated breast for fine needle aspiration. Women may have had prior unilateral breast radiation or mastectomy for DCIS
  • (ECOG) current performance status (PS) ≤ 2 as documented within 3 months prior to randomization or score >= 60%
  • Total =\< 1.5 x institutional (measured within 180 days prior to randomization)
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =\< 1.5 x institutional upper limit of normal (measured within 180 days prior to randomization)
  • Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 1.5 x institutional upper limit of normal (measured within 180 days prior to randomization)
  • Creatinine =\< 2.0 mg/dL (measured within 180 days prior to randomization)
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • Ability to understand and the willingness to sign a written document
  • Confirmation that fixed (Cytolyt™) and frozen tissue specimens have been received in good condition at KUMC and are likely adequate for assessment of the primary endpoint. Confirmation will be provided by Protocol PI(s) and/or KUMC Laboratory personnel
  • Confirmation that a Volpara™ Score Card or a Volpara Data Manager (VDM)-generated Excel file has been received at KUMC and archived for assessment of the secondary endpoint. Confirmation will be provided by Protocol PI(s) and/or KUMC study coordinator. Alternatively, confirmation may be provided by site personnel that a raw image file in Digital Imaging and Communications in Medicine (DICOM) format has been archived at the site such that it can be later used for generation of a Volpara™ Score Card or Excel file

Exclusion criteria

Exclusion Criteria:

  • Bilateral breast implants (danger of implant puncture with RPFNA)
  • Women who are pregnant
  • Currently breastfeeding (concern that tamoxifen or acolbifene may be in breast milk) or nursing within the past 12 months (concern about milk fistula with RPFNA)
  • Prior invasive breast cancer within the past 5 years
  • Other prior invasive cancer > T1 stage (other than non-melanoma skin) within the past 5 years
  • Pathogenic or likely pathogenic germline mutation in BRCA1
  • Type I or Type II diabetes mellitus requiring treatment with prescription medication
  • Prior deep vein thrombosis, pulmonary embolus, or stroke
  • History of chronic liver disease including NASH (nonalcoholic steatohepatitis) and chronic
  • History of chronic or hepatitis C (danger of exacerbation of liver damage from hepatitis or tamoxifen-induced non-alcoholic fatty liver disease or non-alcoholic steatohepatitis)
  • History of (HIV)-infection (danger of exacerbation of underlying clinically inapparent liver damage caused by HIV and/or hepatotoxicity can be induced by interaction of tamoxifen-induced with direct anti-hepatitis C virus [HCV] agents)
  • Current use of prescription anticoagulants such as Coumadin (warfarin), direct-acting oral anticoagulants such as Xarelto (rivaroxaban) or Eliquis (apixaban), or heparin
  • Women who, due to a medical condition, would not be able to discontinue daily use of aspirin (81 mg or higher) and aspirin containing products (81 mg or higher) at least 3 weeks prior to each RPFNA are not eligible
  • Starting or stopping oral (OCs) or hormonal progestin IUDs within 8 weeks of baseline RPFNA
  • Current use or use within the prior 8 weeks of progesterone/progestin injections or progestin implants (due to concerns about high levels of progestin and lack of safety and efficacy data with low dose tamoxifen)
  • Current use of other agents
  • Prior treatment with acolbifene for more than 2 months
  • Prior treatment with tamoxifen for more than 2 months
  • Current use of prescription drugs
  • History of allergic reactions attributed to tamoxifen or acolbifene or compounds of similar chemical composition
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study
  • Use of GLP-1 or GIP receptor agonist within 8 weeks of enrollment or plan to use a GLP-1 or GIP receptor agonist during study participation
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Group 1 (acolbifene)

    Patients receive acolbifene PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D mammography and collection of blood samples during screening and at the end of acolbifene treatment. In addition, patients undergo RPFNA during screening and during day 1-10 of their menstrual cycle, or if not menstruating, at the convenience of the patient and study staff.

    Drug: Acolbifene Hydrochloride · Procedure: Biospecimen Collection · Other: Questionnaire Administration · Procedure: Random Periareolar Fine-Needle Aspiration

  • Active comparator
    Group 2 (tamoxifen)

    Patients receive tamoxifen PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D mammography and collection of blood samples during screening and at the end of tamoxifen treatment. In addition, patients undergo RPFNA during screening and day 1-10 of their menstrual cycle, or if not menstruating, at the convenience of the patient and study staff.

    Procedure: Biospecimen Collection · Procedure: Mammography · Other: Questionnaire Administration · Procedure: Random Periareolar Fine-Needle Aspiration · Drug: Tamoxifen

Interventions

  • DrugAcolbifene Hydrochloride

    Given PO

  • ProcedureBiospecimen Collection

    Undergo collection of blood

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureMammography

    Undergo 3D mammography

    Also known as: MG

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureRandom Periareolar Fine-Needle Aspiration

    Undergo RPFNA

    Also known as: Random Periareolar Fine Needle Aspiration, RPFNA

  • Given PO

    Also known as: TMX

07

What researchers measure

Primary outcomes

  1. Change in the relative abundance of the specific sequence of messenger ribonucleic acid that codes for AGR2

    Will be assessed in benign breast tissue acquired by random periareolar fine-needle aspiration. Change over the intervention period is expressed as the ratio of the relative abundance values (6-month value: baseline value) and then this fold change value is log transformed (base 2) for analysis. For this variable, values of zero indicate no change in the relative abundance of AGR2; positive values indicate an increase in the relative abundance; and negative values a decrease in the relative abundance.

    Time frame: Baseline up to 6 months

Secondary outcomes

  1. Change in Estrogen Response Gene Index (ERGI)

    The genes assayed for this index are: ESR1, ESR2, GREB1, progesterone receptor (PGR), and TFF1. The log2-transformed values of the ratio of relative abundance (6-month value: baseline value) for GREB1, PGR, TFF1, and the ratio of ESR1:ESR2 are averaged to produce the ERGI. In cases where a specific gene or ratio cannot be evaluated for change over time, it is omitted from the average.

    Time frame: Baseline up to 6 months

  2. Relative change in mammographic absolute fibroglandular volume

    Will be assessed via the completely automated Volpara™ software program. This will be performed from Digital Imaging and Communications in Medicine image files analyzed on a Research Server to which the Volpara™ algorithm has been loaded. The Volpara™ score card with volumetric assessments will be automatically generated. Alternatively, a Volpara Data Manager (VDM) program running the same algorithm may be used to generate an Excel file which stores at least all variables provided by the Score Card. The volumetric measures may be less susceptible to technical variance (such as compression) than area of density. Will evaluate absolute change and relative change between baseline and 6-month assessments.

    Time frame: Baseline up to 6 months

  3. Relative change in mammographic percentage (%) dense volume

    Will be assessed via the completely automated Volpara™ software program. This will be performed from Digital Imaging and Communications in Medicine image files analyzed on a Research Server to which the Volpara™ algorithm has been loaded. The Volpara™ score card with volumetric assessments will be automatically generated. Alternatively, a VDM program running the same algorithm may be used to generate an Excel file which stores at least all variables provided by the Score Card. The volumetric measures may be less susceptible to technical variance (such as compression) than area of density. Will evaluate absolute change and relative change between baseline and 6-month assessments.

    Time frame: Baseline up to 6 months

  4. Change in Menopause-Specific Quality of Life (MENQOL)

    The responses to the 32 questions (will ask about symptoms over prior week) are clustered into four domains (vasomotor, psychosocial, physical, sexual). Worsening of problems (higher scores) over the course of the intervention will assessed by average scores for each of the four individual domains as well as the total MENQOL score.

    Time frame: Baseline up to 6 months

  5. Change in Hot Flash Score

    The Hot Flash Score uses the product of the average number of hot flash/night sweat episodes per day and the average intensity (0= N/A, not experienced; 1= Mild; 2= Moderate; 3= Severe; 4= Very Severe).

    Time frame: Baseline up to 6 months

08

Study locations

4 of 4 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Aug 2027, 34 months after the start.

Of 36 phase 2 interventional studies under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 170. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 12, 2023
StartActual
Oct 10, 2024
Primary completionEst.
Aug 23, 2027
CompletionEst.
Sep 1, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05941520
Responsible party
Sponsor
First posted
Jul 12, 2023
Start date
Oct 10, 2024
Primary completion
Aug 23, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Carol J Fabian
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion